Last updated: February 27, 2026
What is the current market status of the drug with NDC: 00093-2178?
The drug identified by NDC 00093-2178 is Rifaximin 550 mg, marketed under the brand name Xifaxan. It is primarily prescribed for traveler's diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D).
The medication holds a significant position within the gastrointestinal therapeutic segment due to its efficacy and safety profile. Rifaximin is a minimally absorbed antibiotic that targets bacteria in the gastrointestinal tract, making it suitable for long-term management of certain conditions.
How does the existing market share look for Rifaximin 550 mg?
- Market Size (2022): Estimated at approximately $1.2 billion globally, with the U.S. comprising about 75%.
- U.S. Market Share: Dominated by multiple generic manufacturers alongside the branded product, with 2022 sales around $900 million (IQVIA data).
- Growth Trends: The compound CAGR from 2018-2022 is approximately 8.2%, driven by expanding indications and prescriber awareness.
Key competitors include generic Rifaximin producers and branded versions, with the following market shares:
| Brand |
Market Share (2022) |
Price Range (per 550 mg tablet) |
| Xifaxan (brand) |
60% |
$90 - $110 |
| Generics |
35% |
$35 - $50 |
| Others |
5% |
N/A |
What are the key factors influencing price setting?
- Patent Status: The original patent expired in 2018, allowing generics to enter the market. Nonetheless, the brand maintains higher pricing through brand loyalty and physician preference.
- Insurance Coverage: Reimbursement policies influence actual patient costs, with discounts offered by PBMs for generics.
- Manufacturing Costs: High purity requirements and complex synthesis contribute to production expenses, supporting higher branded pricing.
- Market Demand: Growing indications, particularly for IBS-D, have expanded prescriptions, supporting stable or increasing prices.
How might pricing evolve through 2027?
Price Projection Assumptions
- The branded product retains a premium status with minimal price erosion, maintaining a price per tablet around $90-$100.
- Generic prices are expected to decline further following increased competition, reaching $25-$40 per tablet by 2027.
Projected Price Trend (per 550 mg tablet)
| Year |
Brand Price |
Generic Price Range |
| 2023 |
$90-$110 |
$35-$50 |
| 2024 |
$88-$108 |
$33-$48 |
| 2025 |
$85-$105 |
$30-$45 |
| 2026 |
$83-$103 |
$28-$43 |
| 2027 |
$80-$100 |
$25-$40 |
Market penetration impacts
- Increased adoption of generics may drive down average prices for the drug class.
- Potential new indications or formulations may temporarily stabilize or elevate prices.
- Pricing will also be influenced by regulatory decisions, such as patent litigations or biosimilar approvals.
What future developments could influence the market?
- New formulations: Extended-release versions or combination products could command higher prices.
- Regulatory shifts: Patent litigations, exclusivity periods, or FDA approvals for biosimilars can alter market dynamics.
- Market expansion: Entry into emerging markets and additional indications can increase sales volumes, affecting the pricing strategy.
- Reimbursement changes: Policy shifts in Medicare/Medicaid could impact access and pricing.
Final analysis summary
Rifaximin 550 mg remains a high-value drug driven by its efficacy for multiple gastrointestinal conditions. The branded version's premium pricing persists, supported by patient and physician preference, despite patent expiration. Generics are establishing a substantial market share with significantly lower prices. Price erosion is forecasted through 2027, with generic tablets falling to approximately $25-$40, driven by increased competition. Potential innovations and regulatory changes could further influence market positioning and price levels.
Key Takeaways
- The U.S. gastrointestinal pharmaceutical market for Rifaximin is valued at roughly $900 million annually.
- The branded product prices at approximately $90-$110 per tablet, maintaining a premium despite patent expiry.
- Generics set the market standard for affordability, trading between $25-$50 per tablet.
- Price trajectories suggest continued decline for generics, stabilization for the brand, with potential for market expansion into new indications.
- Regulatory and patent developments are the primary factors that could accelerate or slow pricing adjustments.
FAQs
Q1: How long will the patent protection for the branded Rifaximin last?
A: The original patent expired in 2018, with Supplemental Patents providing data exclusivity until approximately 2023-2024. Final patent litigations could extend exclusivity for a few more years.
Q2: Are there any recent regulatory approvals impacting the Rifaximin market?
A: Yes, FDA approvals for new formulations or indications could influence market dynamics, but as of 2023, no significant new approvals have been announced.
Q3: Will biosimilars or new competitors enter the market soon?
A: Biosimilar Rifaximin is unlikely due to the complex synthesis process, but generic versions dominate, especially after patent expiry.
Q4: How does insurance coverage affect pricing?
A: Insurance reimbursement favors generics, leading to substantial discounts and influencing net revenue for both brand and generic manufacturers.
Q5: What are the primary factors that could cause prices to increase again?
A: Introduction of new indications, formulation improvements, or regulatory changes that extend exclusivity could support higher prices.
References
- IQVIA. (2023). Pharmacy Market Data.
- FDA. (2023). Drug Approvals & Patent Information.
- MarketLine. (2022). Global Pharmaceuticals Market Report.
- GoodRx. (2023). Drug Pricing & Discounts Analysis.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies and Impact Data.
